Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks: Top 5 Stocks

2. Merck & Co., Inc. (NYSE:MRK)

Number of Hedge Fund Holdings in Q4 2024: 91

Number of Hedge Fund Holdings in Q4 2025: 100

Performance Since Cramer’s Remarks: 46%

Date/Month of Cramer’s Remarks: April 9th, 2025

Merck & Co., Inc. (NYSE:MRK) aims to make an entry into the weight loss drug market through the HS-10535 drug, which it licensed from Hanosh Pharmaceutical through a $2 billion agreement. The shares are up by 33% over the past year and by 46% since Cramer discussed the firm on April 9th. Merck & Co., Inc. (NYSE:MRK)’s shares closed 3.8% higher on November 18th after data for its heart drug Winrevair. 2026 has been a good month for the stock as it is up by 12.4% year-to-date. Between February 2nd and February 6th, the shares gained 7.6%. On February 3rd, Merck & Co., Inc. (NYSE:MRK) reported its fiscal fourth quarter earnings report. The results saw the firm post $16.4 billion in revenue and $2.04 in adjusted profit per share to beat analyst estimates of $16.2 billion and $2.01. Additionally, Merck & Co., Inc. (NYSE:MRK) also revealed that it had expected to earn $65.5 billion to $67 billion in revenue, which sat below analyst estimates. The firm remarked that the loss of exclusivity for several medicines would impact its revenue more than what analysts were expecting. Cramer advised viewers to hold on to their Merck & Co., Inc. (NYSE:MRK) shares on Mad Money:

“You know, first of all, you’re not alone. St. Merck, as we used to call it, has turned into just a complete nightmare. I think that if you buy Merck at a 4% yield though, you’re gonna do well. It did touch $76 today. It’s back to $81. I feel for what you’re doing… It is remarkable how poorly this stock acts. I do want you to stay the course with it right at this point. And I’m sorry because it is been a real tough one.”